Fig 2.

Risk of adverse safety outcomes comparing heterologous primary vaccine schedules of ChAdOx1-S priming and an mRNA booster dose with homologous primary mRNA vaccine schedules. Incidence rate ratios (IRRs) for the outcomes within 28 days were adjusted for calendar period, sex, birth year (as a proxy for age), region of residency, birth country, vaccine priority group, hospital contact in the past six months, and comorbidities. Cerebrovascular infarction includes non-haemorrhagic strokes and transient ischaemic attacks. Other bleeding events include a composite of bleeding-related diagnoses other than intracranial haemorrhages. CI=confidence interval; NE=not estimated